ROARABLE // PRO
[FREE TERMINAL]
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸

TEVA // Teva Pharmaceutical Industries Limited

DES <GO> NYSE CIK 0000818686 ↗
Health Care • Biotechnology: Pharmaceutical Preparations
$41.47 ▲ +1.50 (+3.75%)
MKT CAP: $48.32B • VOL: 5.23M
TEVA // ROARABLE RATING & 5-PILLAR RQD CONFIDENCE 02:00 EST DETERMINISTIC ENGINE
▼ DOWNGRADE // C (RQD 62) -> C- (RQD 61)
ROARABLE C-
RQD CONFIDENCE
61 / 100 -1D
5 X 20-PT QUANT PILLARS
E 0 D 35 C 59 B 70 A 86+
Roarable Hold — Cautious Neutral
01 MASSIVE / SEC XBRL
Forensic Fundamentals
[LOCKED] FLAGGED
UNLOCK BELOW TO REVEAL
02 OPRA GEX + SEC 13F
Whale & Options Flow
10 / 20
NEUTRAL
NET GEX +0% • CALL SWEEP 52% • P/C 0.56
03 SEC FORM 4 (90D)
Insider Conviction
[LOCKED] FLAGGED
UNLOCK BELOW TO REVEAL
04 FRED 90D r-MATRIX
Macro Regime Fit
14 / 20
SOLID
TAILWIND • r(10Y)=+0.00 (+23bp) • r(OAS)=+0.00
05 10-K REDLINE AUDIT
Forensic 10-K Risk
16 / 20
STRONG
20 BASE - 4 DEDUCT • 0 CRIT / 0 MED • STABLE
ALERT

Why did TEVA's Forensic Fundamentals & Insider Conviction sub-score just flash a warning? Enter your email to unlock the full 5-Pillar Rating Breakdown + get instant alerts whenever TEVA is Upgraded or Downgraded.
SIG <GO> CROSS-FEED TRIANGULATION // PROPRIETARY ANOMALY ENGINE (1 ACTIVE ON TEVA)
ALL MARKET ANOMALIES <SIG>
▼ BEARISH // F-RATED EARNINGS MIRAGE // ACCRUAL WATCHSIFTER 02 // ACCRUAL & RECEIVABLES FORENSICS
SEVERITY: 84/100 Z-SCORE: +2.55σ

TEVA Accounting Gap: Net Income (+186%) Outpaced OCF (+32.2%) With +8% Working-Capital Build

CASH CONVERSION GAP
+153.8% (NI vs OCF)
RECEIVABLES / WC BLOAT
+8.0% VS REV
60D C-SUITE FORM 4 SALES
0 OPEN-MKT DUMPS
[GEEK DESK FORENSIC NOTE // SEC XBRL × FORM 4 CROSS-CHECK]
SEC EDGAR XBRL CompanyFacts10-K/10-Q Working Capital ScheduleSEC Form 4 Executive Sales

SEC EDGAR XBRL triangulation on Teva Pharmaceutical Industries Limited (TEVA) exposes a +153.8% Cash Conversion Gap as YoY Net Income growth (+186.0%) diverged from Operating Cash Flow growth (+32.2%). Non-cash current assets and receivables expanded +8.0% relative to top-line revenue growth. Monitor upcoming 10-Q cash realization closely for accrual mean-reversion.

TEVA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +20.02%📐 HORIZONTAL RANGE
2026-10-30O $41.17H $42.59L $41.17C $42.09VOL 7.36M
RES: $43.46SUP: $23.90SMA50: $39.08SMA200: $34.58
$43.77$38.89$34.02$29.14$24.27RES $43.46SUP $23.90$42.092026-04-302026-06-152026-07-312026-09-162026-10-30
TEVA // INSTITUTIONAL BULL VS. BEAR FORENSIC DEBATE
NEUTRAL / PAIR TRADE CONVICTION: 47/100
BEAR 0
100 BULL

Teva Pharmaceutical Industries Limited (TEVA) exhibits 51.8% gross margins and 9.4% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 20.8x enterprise multiple and 6.9% implied options volatility.

▲ INSTITUTIONAL BULL THESIS (LONG)
01. Operating Leverage & Capital Efficiency Moat

Sustained 51.8% gross profitability converts into 12.5% operating margin and 9.4% ROIC, outpacing sector cost of capital.

ROIC: 9.4% // GM: 51.8%
02. Top-Line Expansion & Cash Conversion

YoY revenue trajectory of +4.3% paired with 1.81% free cash flow yield supports self-funded R&D and capital return.

REV YOY: +4.3% // FCF YLD: 1.81%
03. Balance Sheet Solvency & Forensic Quality

Altman Z-Score of 1.02 and Piotroski F-Score of 8/9 indicate low near-term refinancing stress.

ALTMAN Z: 1.02 // F-SCORE: 8/9
▼ INSTITUTIONAL BEAR THESIS (SHORT / RISK)
01. Multiple Compression & Duration Sensitivity

Trading at 34.3x trailing P/E (31.9x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.

P/E: 34.3x // EV/EBITDA: 20.8x
02. Options Skew & Event Volatility Risk

Options market prices a ±6.9% implied move with a 0.56 put/call ratio around $41.00 max pain.

IMPL MOVE: ±6.9% // P/C: 0.56
03. Competitive Margin & CapEx Cycle Pressure

Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend 8.2% net margins.

NET MARGIN: 8.2% // D/E: 1.74x
KEY CATALYST // Upcoming 10-Q/10-K XBRL margin progression, guidance revision vs 31.9x forward consensus, and institutional 13F positioning.
MACRO REGIME // Monitor US 10Y Real Yields (DFII10) and High-Yield Credit Spreads (OAS) for beta-adjusted multiple impact (Beta 1.00).
FORM 4 & 13F FLOW OPEN OWN <GO>
FILER SIDE $ VALUE
INSPECT FULL OWNERSHIP LEDGER IN OWN <GO>
UNUSUAL OPTIONS TAPE OPEN OPT <GO>
STRIKE / EXP TYPE PREMIUM
INSPECT GEX & CHAIN IN OPT <GO>
KEY VALUATION & PROFITABILITY RATIOS XBRL FA <GO>
TRAILING P/E 34.3x
FORWARD P/E 31.9x
EV / EBITDA 20.8x
FCF YIELD 1.81%
GROSS MARGIN 51.8%
OPERATING MARGIN 12.5%
NET MARGIN 8.2%
ROIC % 9.4%
REV GROWTH YOY +4.3%
DILUTED EPS TTM $1.21
DEBT / EQUITY 1.74x
DIVIDEND YIELD 0.00%
RSI-14 MOMENTUM 63.7
5Y EQUITY BETA 1.00
FRED MACRO SENSITIVITY (PEARSON r) ECST <GO>
MACRO CORRELATION CALIBRATION ACTIVE BELOW.
FRED MACRO REGIME STRESS-TEST SIMULATOR // TEVAPEARSON R VARIANCE ENGINE
01 // SELECT FEDERAL RESERVE & CREDIT SHOCK SCENARIO
02 // POSITION NOTIONAL EXPOSURE
HEADLINE STRESS SCORE
75/100SEVERE DRAWDOWN PRESSURE
PRIMARY FACTOR EXPOSURE
DFII10 // -0.61 r
Latest: 2.08%
EST. DIRECTIONAL MOVE
-8.50%
Implied Px: $37.95
EST. DOLLAR VARIANCE
-$4,248
On $50,000 Notional
[LOCKED // MULTI-FACTOR DRAWDOWN HEDGE & MACRO TRIGGER ALERT]

Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for TEVA & activate live FRED threshold breach alerts.
HEAD-TO-HEAD PEER COMPARISONS COMP <GO>
TEVA VS LLY
MARGINS ROIC VALUATION
TEVA VS JNJ
MARGINS ROIC VALUATION
TEVA VS ABBV
MARGINS ROIC VALUATION
TEVA VS UNH
MARGINS ROIC VALUATION